Back to the drug test guide

Buprenorphine Test Evidence

Has Caused a False Positive

Amisulpride

Source Birch et al., J Anal Toxicol 2013

What It Found

  • Two patients receiving amisulpride had unconfirmed buprenorphine screens.
  • LC-MS/MS detected amisulpride and excluded buprenorphine and its metabolites.
  • Laboratory testing documented weak cross-reactivity.

Keep in Mind

  • The reported psychiatric treatment exposure is not directly comparable to a single IV antiemetic dose of amisulpride.

Test Studied

  • Thermo CEDIA buprenorphine

Loperamide

Source Geno et al., J Appl Lab Med 2022

What It Found

  • The N-desmethyl metabolite of loperamide produced positive buprenorphine screens above 12.2 mg/L in spiked urine.
  • A clinical specimen contained an interfering concentration.

Keep in Mind

  • Evidence concerns high concentrations and a specific metabolite.
  • A usual antidiarrheal dose is not established as a cause.

Test Studied

  • Thermo CEDIA buprenorphine

Stevia

Source Plattner et al., J Anal Toxicol 2021

What It Found

  • A study of unexpected screens investigated steviol glucuronide, a urinary metabolite of stevia sweeteners.
  • It cross-reacted above 15 mg/L.

Keep in Mind

  • This food-additive finding pertains to the Buprenorphine II reagent.
  • It does not imply that every stevia product or serving causes a positive.

Test Studied

  • Thermo CEDIA Buprenorphine II

Benzylpiperazine

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a Benzylpiperazine spike of 29,000 ng/mL, the mean assay response was 6.1 ng/mL equivalent (0.02% cross-reactivity), above the 5 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Buprenorphine urine assay, cutoff 5 ng/mL

Butylone

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a Butylone spike of 29,000 ng/mL, the mean assay response was 6 ng/mL equivalent (0.02% cross-reactivity), above the 5 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Buprenorphine urine assay, cutoff 5 ng/mL

Ceftaroline fosamil

Source Hughey and Colby, Clin Chem 2019

What It Found

  • In a clinical-records study followed by laboratory testing, added ceftaroline fosamil produced a presumptive buprenorphine result at an estimated 681.5 micrograms/mL.

Keep in Mind

  • This experiment establishes analytical reactivity.
  • It did not establish how often prescribed doses lead to this urine concentration or a positive patient result.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Chloroquine

Source Melanson et al., J Anal Toxicol 2012

What It Found

  • Laboratory comparison of CEDIA and the Lin-Zhi buprenorphine assay identified chloroquine interference with CEDIA.

Keep in Mind

  • No clinical event frequency or transferable cutoff was established for people taking chloroquine.

Test Studied

  • Microgenics CEDIA buprenorphine

Donepezil

Source Hughey and Colby, Clin Chem 2019

What It Found

  • In a clinical-records study followed by laboratory testing, added donepezil produced a presumptive buprenorphine result at an estimated 709.6 micrograms/mL.

Keep in Mind

  • This experiment establishes analytical reactivity.
  • It did not establish how often prescribed doses lead to this urine concentration or a positive patient result.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Flephedrone

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a 4-Fluoromethcathinone spike of 27,000 ng/mL, the mean assay response was 5.8 ng/mL equivalent (0.02% cross-reactivity), above the 5 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Buprenorphine urine assay, cutoff 5 ng/mL

Hydroxychloroquine

Source Melanson et al., J Anal Toxicol 2012

What It Found

  • A method-comparison study identified interference with this reagent.

Test Studied

  • Microgenics CEDIA buprenorphine

Source Radke et al., Toxicol Rep 2019

What It Found

  • Hydroxychloroquine also affected selected assays at high concentrations in an overdose investigation.

Keep in Mind

  • An absorbance alarm on an oxycodone assay does not show an oxycodone false positive.

Both sources Melanson et al., J Anal Toxicol 2012 Radke et al., Toxicol Rep 2019

Keep in Mind

  • The nature of the effect differs by test.

Levofloxacin

Source Colby et al., Clin Biochem 2019

What It Found

  • When levofloxacin was added to drug-free urine at concentrations considered achievable during treatment, this assay produced a presumptive positive.

Keep in Mind

  • This differs from the negative dedicated oxycodone and methadone assays tested in the same experiment.

Test Studied

  • Thermo CEDIA buprenorphine

Methoxetamine

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a Methoxetamine spike of 28,000 ng/mL, the mean assay response was 5.9 ng/mL equivalent (0.02% cross-reactivity), above the 5 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Buprenorphine urine assay, cutoff 5 ng/mL

Methylenedioxypyrovalerone

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a Methylenedioxypyrovalerone spike of 21,000 ng/mL, the mean assay response was 6 ng/mL equivalent (0.03% cross-reactivity), above the 5 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Buprenorphine urine assay, cutoff 5 ng/mL

Procainamide

Source Hughey and Colby, Clin Chem 2019

What It Found

  • In a clinical-records study followed by laboratory testing, added procainamide produced a presumptive buprenorphine result at an estimated 92.8 micrograms/mL.
  • An N-acetyl hydroxy metabolite also reacted.

Keep in Mind

  • This experiment establishes analytical reactivity.
  • It did not establish how often prescribed doses lead to this urine concentration or a positive patient result.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Propafenone

Source Hughey and Colby, Clin Chem 2019

What It Found

  • In a clinical-records study followed by laboratory testing, added propafenone produced a presumptive buprenorphine result at an estimated 180.7 micrograms/mL.

Keep in Mind

  • This experiment establishes analytical reactivity.
  • It did not establish how often prescribed doses lead to this urine concentration or a positive patient result.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Rotigotine

Source Hughey and Colby, Clin Chem 2019

What It Found

  • In a clinical-records study followed by laboratory testing, added rotigotine produced a presumptive buprenorphine result at an estimated 0.13 micrograms/mL.

Keep in Mind

  • This experiment establishes analytical reactivity.
  • It did not establish how often prescribed doses lead to this urine concentration or a positive patient result.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Sulpiride

Source Birch et al., J Anal Toxicol 2013

What It Found

  • The investigators demonstrated low but measurable analytical cross-reactivity with sulpiride.
  • High urinary levels relative to the assay cutoff could make it relevant.

Keep in Mind

  • The two patients with mass-spectrometry confirmation described in the abstract were receiving amisulpride.
  • The sulpiride evidence presented here is analytical.

Test Studied

  • Thermo CEDIA buprenorphine

Trimethoprim

Source Hughey and Colby, Clin Chem 2019

What It Found

  • In a clinical-records study followed by laboratory testing, added trimethoprim produced a presumptive buprenorphine result at an estimated 47.2 micrograms/mL.
  • Its frequent partner sulfamethoxazole did not react in this experiment.

Keep in Mind

  • This experiment establishes analytical reactivity.
  • It did not establish how often prescribed doses lead to this urine concentration or a positive patient result.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Depends on the Brand of Test

Codeine

Source Berg et al., Subst Abuse Rehabil 2015

What It Found

  • One healthy volunteer screened positive after a therapeutic 60 mg codeine dose with acetaminophen.
  • Spiking and patient urine data implicated codeine and its metabolites, which can have additive effects.

Keep in Mind

  • A higher cutoff improved specificity in the study.
  • Acetaminophen was part of the formulation, not the identified cross-reactant.

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Codeine at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Wang et al., J Anal Toxicol 2007

What It Found

  • The recombinant assay showed less than 1% relative cross-reactivity with Codeine.

Keep in Mind

  • A small percentage response cannot be converted to a positive concentration without the assay’s calibration and challenge conditions.

Test Studied

  • A recombinant G6PDH-based homogeneous urine buprenorphine immunoassay

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The IDS validation reports no cross-reactivity with Codeine.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

2 sources Berg et al., Subst Abuse Rehabil 2015 Pavlic et al., Int J Legal Med 2005

Test Studied

  • Thermo CEDIA buprenorphine, especially 5 ng/mL cutoff

Dihydrocodeine

Source Pavlic et al., Int J Legal Med 2005

What It Found

  • Dihydrocodeine reacted above 60 mg/L in the reported CEDIA assay.

Source Miller et al., J Anal Toxicol 2006

What It Found

  • An Immunalysis microplate ELISA did not react at the lower concentrations studied, up to 10 mg/L.

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Dihydrocodeine at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Böttcher and Beck, J Anal Toxicol 2005

What It Found

  • Unconfirmed buprenorphine screens occurred in patients who had been prescribed dihydrocodeine.

Keep in Mind

  • This is clinical evidence for the CEDIA reagent; the Singlestep ELISA gave a different result in fortified urine.

Test Studied

  • Microgenics CEDIA buprenorphine assay, 5 ng/mL cutoff, with GC-MS comparison

Source Wang et al., J Anal Toxicol 2007

What It Found

  • The recombinant assay showed less than 1% relative cross-reactivity with Dihydrocodeine.

Keep in Mind

  • A small percentage response cannot be converted to a positive concentration without the assay’s calibration and challenge conditions.

Test Studied

  • A recombinant G6PDH-based homogeneous urine buprenorphine immunoassay

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The validation reports no cross-reaction with Dihydrocodeine at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

2 sources Pavlic et al., Int J Legal Med 2005 Miller et al., J Anal Toxicol 2006

Keep in Mind

  • Different assays and concentrations were tested.
  • There is no patient risk estimate.

2 sources Pavlic et al., Int J Legal Med 2005 Böttcher and Beck, J Anal Toxicol 2005

Test Studied

  • Microgenics CEDIA buprenorphine (5 ng/mL cutoff)

Morphine

Source Tenore, J Addict Dis 2012

What It Found

  • Repeated screens became positive with high-dose morphine, negative when it was stopped, then positive again when restarted.
  • GC-MS excluded buprenorphine.

Test Studied

  • Clinical EIA

Source Pavlic et al., Int J Legal Med 2005

What It Found

  • An earlier analytical study demonstrated morphine cross-reactivity.

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Morphine at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Wang et al., J Anal Toxicol 2007

What It Found

  • The recombinant assay showed less than 1% relative cross-reactivity with Morphine.

Keep in Mind

  • A small percentage response cannot be converted to a positive concentration without the assay’s calibration and challenge conditions.

Test Studied

  • A recombinant G6PDH-based homogeneous urine buprenorphine immunoassay

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The IDS validation reports no cross-reactivity with Morphine.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Source Schubert et al., J Anal Toxicol 2019

What It Found

  • In an opioid-maintenance cohort including high-dose morphine, the newer reagent had substantially better specificity.
  • Its one borderline unconfirmed result had no identified interferent.

Keep in Mind

  • The 21 first-generation false positives were attributed collectively to opiate cross-reactivity, without proving morphine alone in each specimen.

Test Studied

  • First-generation CEDIA buprenorphine (5 ng/mL) and CEDIA Buprenorphine II (10 ng/mL)

3 sources Tenore, J Addict Dis 2012 Berg et al., Subst Abuse Rehabil 2015 Pavlic et al., Int J Legal Med 2005

Keep in Mind

  • High urine concentrations or combined opioid metabolites can matter.

Test Studied

  • Microgenics CEDIA buprenorphine

2 sources Tenore, J Addict Dis 2012 Pavlic et al., Int J Legal Med 2005

Keep in Mind

  • The findings are not a frequency estimate for standard doses.

Tramadol

Source Shaikh et al., J Anal Toxicol 2008

What It Found

  • Among 29 urine samples from patients on tramadol, seven positive buprenorphine screens were shown false by LC-MS/MS.
  • No false positives were found on ACON at 10 ng/mL or CEDIA at 20 ng/mL.

Keep in Mind

  • Three screen-positive specimens lacked enough urine for confirmation.
  • Reactivity depends on the device and cutoff.

Tests Studied

  • CEDIA at 5 versus 20 ng/mL
  • QuikStrip, ABMC and ACON point-of-care devices

Methadone

Source Pavlic et al., Int J Legal Med 2005

What It Found

  • A CEDIA study found interference above 320 mg/L of methadone.

Keep in Mind

  • This was an exceptionally high analytical concentration and does not imply routine maintenance treatment will trigger this test.

Test Studied

  • Microgenics CEDIA buprenorphine

Source Miller et al., J Anal Toxicol 2006

What It Found

  • A different ELISA did not react at its tested upper concentration of 10 mg/L.
  • EDDP, its metabolite, was also tested without a reaction.

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Methadone at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The IDS validation reports no cross-reactivity with Methadone.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Methylone

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a Methylone spike of 23,000 ng/mL, the mean assay response was 3.7 ng/mL equivalent (0.02% cross-reactivity), below the 5 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Buprenorphine urine assay, cutoff 5 ng/mL

The Test Is Made to Find It

Buprenorphine

All 4 sources Melanson et al., J Anal Toxicol 2012 Miller et al., J Anal Toxicol 2006 Debrabandere et al., Analyst 1993 Wang et al., J Anal Toxicol 2007

What It Found

  • Prescribed buprenorphine can appropriately trigger this test.
  • Suboxone contains two active ingredients: buprenorphine explains expected buprenorphine detection; the separate naloxone entry describes interference on some other tests.

Keep in Mind

  • The result alone does not measure adherence to a particular dose.

Test Studied

  • Dedicated buprenorphine screen

Source Debrabandere et al., Analyst 1993

What It Found

  • The assay antibody showed up to about 90% reactivity with norbuprenorphine, the N-dealkylated metabolite, while its glucuronide responses were low.

Keep in Mind

  • Different buprenorphine assays recognize the metabolites to different degrees.

Test Studied

  • Historical urine radioimmunoassay and HPLC

Source Wang et al., J Anal Toxicol 2007

What It Found

  • The antibody recognized free buprenorphine and norbuprenorphine nearly equally.

Keep in Mind

  • This is reagent-specific.
  • Other assays respond differently to the metabolite.

Test Studied

  • Recombinant G6PDH-based homogeneous urine buprenorphine immunoassay

2 sources Debrabandere et al., Analyst 1993 Wang et al., J Anal Toxicol 2007

Keep in Mind

  • Reagents vary in the extent to which they recognize parent drug and metabolites.

Source Melanson et al., J Anal Toxicol 2012

Test Studied

  • LC-MS/MS

Tested: No False Positive Found

Cytarabine

Source Hughey and Colby, Clin Chem 2019

What It Found

  • An association in medical records did not reproduce when cytarabine was added to drug-free urine.
  • Concomitant levofloxacin was common.

Keep in Mind

  • A prescribing association alone is insufficient evidence of direct interference.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL

Dextromethorphan

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Dextromethorphan at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The validation reports no cross-reaction with Dextromethorphan at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Dextromoramide

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Dextromoramide at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The validation reports no cross-reaction with Dextromoramide at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Ethylmorphine

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Ethylmorphine at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The validation reports no cross-reaction with Ethylmorphine at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Heroin

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with 6-monoacetylmorphine, the heroin metabolite at 1 or 10 mg/L in the Singlestep assay.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The IDS validation reported no cross-reaction with 6-monoacetylmorphine, the primary heroin metabolite, at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Both sources Cirimele et al., J Anal Toxicol 2003 Cirimele et al., Forensic Sci Int 2004

Keep in Mind

  • Only the heroin metabolite 6-acetylmorphine (6-MAM) was tested.
  • The experiment gives no direct result for the parent drug.

Pholcodine

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Pholcodine at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The validation reports no cross-reaction with Pholcodine at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Propoxyphene

Source Cirimele et al., J Anal Toxicol 2003

What It Found

  • No cross-reaction was reported with Propoxyphene at 1 or 10 mg/L in the Singlestep assay.

Keep in Mind

  • These reagent-specific challenges do not predict responses on other buprenorphine assays.

Test Studied

  • Microgenics Singlestep urine buprenorphine ELISA

Source Cirimele et al., Forensic Sci Int 2004

What It Found

  • The validation reports no cross-reaction with Propoxyphene at 1 or 10 mg/L.

Keep in Mind

  • The IDS assay was evaluated in human urine, blood and hair.
  • The abstract does not separately assign a challenge matrix for each compound.
  • It does not exclude a result on other buprenorphine reagents.

Test Studied

  • IDS One-Step buprenorphine ELISA

Sulfamethoxazole

Source Hughey and Colby, Clin Chem 2019

What It Found

  • An apparent association in medical records was investigated by testing the two ingredients of trimethoprim/sulfamethoxazole separately.
  • Trimethoprim reacted but sulfamethoxazole did not.

Keep in Mind

  • The combination remains searchable under trimethoprim.
  • A negative single-ingredient challenge has only reagent-specific scope.

Test Studied

  • Thermo CEDIA buprenorphine, 5 ng/mL